Actelion values partnerships with individual young investigators to advance quality medical care and to enhance patients' lives by supporting clinical endothelin research related to heart, lung and vascular diseases.
The Actelion Endothelin Research Awards programme provides promising young investigators grants up to 100,000 Swiss Francs (CHF) towards mentored research projects for a maximum period of 12 months. Only clinical projects with patient involvement will be evaluated and considered for funding.
Grants are awarded based on scientific merit, originality, feasibility / ability to prove the hypothesis, and applicability to endothelin research. A condition of grant application is the supervision by an appropriate mentor. Drugs used in the submitted studies must have been approved in the country where the study will be conducted. Receiving a grant in no way implies that the recipient is obliged to recommend or prescribe any Actelion products.
AERA is part of a global programme showing Actelion's commitment to endothelin research. Investigator-initiated clinical trials for young researchers at universities and research institutes are supported in all countries except the US - a dedicated programme has been developed for the US (www.entelligencemd.org).
If your project is approved for funding, you will be responsible for all aspects of your research. You will be provided with an agreement, which you have to sign and return within 90 days together with selected additional documents, which will include (but are not limited to):
- Institutional Review / Ethical committee approval
for the submitted study
- Clinical study protocol
- Sample informed consent documents
Please note that no funds will be disbursed prior to complete submission of the above documents. Failure to submit requested documents within the given deadline may result in withdrawal of funds. A sample agreement is available for download. By submitting the application form and by signing the agreement, the principal investigator agrees that experiments conducted with AERA funds are compliant with the ethical conduct of research as expressed in the latest version of the World Medical Association Declaration of Helsinki.
For more information please download the AERA Charter.
Legal Statement and Disclaimer
Great efforts have been made and will continue to be made in order to include accurate and up-to-date information on this website. However, Actelion Pharmaceuticals Ltd. makes no warranties or representations, express or implied, as to the accuracy or completeness of the information contained or referenced therein and disclaims any liability for the use of this site or any site linked to it or the content thereof. Actelion Pharmaceuticals Ltd. may change this site at any time without notice but does neither assume any responsibility to update it nor assume any liability in any way for possible consequences of such changes. All users agree that all access and use of this site and on any site linked to this site and the content thereof is at their own risk and responsibility. Neither Actelion nor any other party involved in creating, producing or delivering this site or any other site linked to this site shall be liable in any manner whatsoever for any direct, incidental, consequential, indirect or punitive damages arising out of your access, use or inability to use this site or any site linked to this site, or any errors or omissions on the content thereof.
This website and the information contained and referenced therein are for informational purposes only. Any reproduction, retransmission or other use is strictly prohibited. Request for permission to reproduce any information contained on the website should be addressed to the webmaster. All links to third party pages are provided for convenience only. We do not express any opinion on the content of any third party pages and expressly disclaim any liability for all third party information and the use of it.